{"id":"epogen-amgen","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Headache"},{"rate":"1-5","effect":"Thrombotic events (DVT, PE, stroke)"},{"rate":"<1","effect":"Pure red cell aplasia"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL4860030","moleculeType":"Unknown","molecularWeight":"615.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for regulating red blood cell production. By activating the erythropoietin receptor on erythroid progenitor cells in the bone marrow, it promotes their proliferation and differentiation into mature red blood cells. This mechanism is used to treat anemia in patients with chronic kidney disease, cancer patients on chemotherapy, and those undergoing surgery.","oneSentence":"Epogen (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:29.271Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in cancer patients on chemotherapy"},{"name":"Anemia in patients undergoing elective surgery"}]},"trialDetails":[{"nctId":"NCT03171818","phase":"PHASE2","title":"Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2017-07-01","conditions":"PAIS, Neonatal Stroke, Perinatal Stroke","enrollment":80},{"nctId":"NCT02241200","phase":"PHASE1","title":"A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-08-18","conditions":"Symptomatic Anemia","enrollment":64},{"nctId":"NCT02506868","phase":"PHASE3","title":"Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-08-08","conditions":"Chronic Kidney Disease, End Stage Renal Failure on Dialysis, Anemia","enrollment":196},{"nctId":"NCT01473407","phase":"PHASE3","title":"A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-01-31","conditions":"Chronic Kidney Disease, Chronic Renal Failure","enrollment":612},{"nctId":"NCT01473420","phase":"PHASE3","title":"A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-01-17","conditions":"Chronic Renal Failure, Chronic Kidney Disease","enrollment":320},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT01170078","phase":"PHASE1","title":"A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2010-07","conditions":"Chronic Renal Failure","enrollment":107},{"nctId":"NCT00135317","phase":"PHASE3","title":"AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-11","conditions":"Cancer","enrollment":""},{"nctId":"NCT00117065","phase":"PHASE4","title":"Study of Transplant Related Anemia Treated With Aranesp® (STRATA)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Anemia","enrollment":""},{"nctId":"NCT00117130","phase":"PHASE4","title":"Study to Evaluate Effectiveness of Aranesp®","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Kidney Disease","enrollment":""},{"nctId":"NCT00239239","phase":"PHASE2","title":"Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08","conditions":"Non-Myeloid Malignancies, Anemia, Cancer","enrollment":44},{"nctId":"NCT00117104","phase":"PHASE4","title":"Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"End Stage Renal Disease","enrollment":""},{"nctId":"NCT00120705","phase":"PHASE2","title":"Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-11","conditions":"Neoplasms, Anemia","enrollment":204},{"nctId":"NCT00117117","phase":"PHASE4","title":"A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-09","conditions":"Anemia","enrollment":2423},{"nctId":"NCT00117078","phase":"PHASE4","title":"Aranesp® Monthly Preference Study - 2","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Kidney Disease","enrollment":""},{"nctId":"NCT00124098","phase":"PHASE3","title":"An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Kidney Disease","enrollment":""},{"nctId":"NCT00121602","phase":"PHASE3","title":"Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03","conditions":"Anemia, Kidney Disease","enrollment":446},{"nctId":"NCT00111137","phase":"PHASE3","title":"Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2003-02","conditions":"Cancer, Non-Myeloid Malignancies","enrollment":718},{"nctId":"NCT00119587","phase":"PHASE3","title":"Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-08","conditions":"Anemia","enrollment":""},{"nctId":"NCT00120692","phase":"PHASE2","title":"Treatment for Patients Suffering From Anemia Due to Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-10","conditions":"Breast Cancer, Anemia","enrollment":""},{"nctId":"NCT00120679","phase":"PHASE2","title":"Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-10","conditions":"Non-Small Cell Lung Cancer, Anemia","enrollment":""},{"nctId":"NCT00121030","phase":"PHASE2","title":"Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-10","conditions":"Gynecological Malignancies, Genital Neoplasms, Female, Anemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epoetin Alfa"],"phase":"phase_3","status":"active","brandName":"Epogen Amgen","genericName":"Epogen Amgen","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Epogen (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients on chemotherapy, Anemia in patients undergoing elective surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}